delpacibart etedesiran   Click here for help

GtoPdb Ligand ID: 14730

Synonyms: AOC 1001 | AOC-1001 | del-desiran
Compound class: Nucleic acid
Comment: Delpacibart etedesiran (AOC 1001) is structurally a monoclonal antibody (mAb)-oligonucleotide conjugate (AOC) in which the mAb binds the transferrin receptor (TFRC;) for targeted delivery of a duplex small interfering RNA (siRNA) payload that degrades the mRNA that encodes DM1 protein kinase (DMPK) [1].

This entry provides information on the siRNA as the component that mediates the agent's intended pharmacodynamic effect. Further details about the parental anti-TFRC mAb are provided in the delpacibart entry. To improve pharmacokinetics and RNA binding the nucleotides in etedesiran are chemically modified (2'-O-methyl/2'-MOE monomers), with a mixed phosphorothioate/phosphate backbone. The mAb is attached to the siRNAs via malemide linkers at Cys-R positions on the passenger strands.

Delpacibart etedesiran is proposed to reduce the global splicing defects that arise from toxic gain-of-function DMPK transcript accummulation in myocytes in myotonic dystrophy type 1.
No information available.
Summary of Clinical Use Click here for help
Delpacibart etedesiran (AOC 1001) was progressed as a clinical candidate for its potential to treat myotonic dystrophy type 1.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05027269 Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2 Interventional Avidity Biosciences, Inc. The MARINA study 1
NCT05479981 Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 2 Interventional Avidity Biosciences, Inc. The MARINA-OLE study
NCT07008469 Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 Phase 3 Interventional Avidity Biosciences, Inc. The HARBOR-OLE study
NCT06411288 Global Study of Del-desiran for the Treatment of DM1 Phase 3 Interventional Avidity Biosciences, Inc. The HARBOR study